Liquidia Technologies, Inc. competitors

Jeff Albers is the chief executive officer of [Blueprint Medicines](https://www.crunchbase.com/organization/blueprint-medicines), a company engaged in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets. He was previously the president of Algeta. Prior to Algeta, he served at Genzyme, where he spent seven years in senior commercial and corporate development positions. Before joining Genzyme, he spent five years as an Attorney at the law firm Mintz Levin Cohn Ferris Glovsky & Popeo. He also has prior experience as a sales representative for Pfizer. Albers holds a bachelor’s degree in marketing from Indiana University and an MBA from Georgetown University.

Prior to joining Genocea,Chip co-founded and served as Chief Business Officer of Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA). Before that, Chip was a Principal at Care Capital, LLC, a venture capital firm investing in biopharmaceutical companies, after serving in a variety of commercial roles at SmithKline Beecham (now GlaxoSmithKline). Chip holds a B.A. from Harvard University and an M.B.A. from The Wharton School at the University of Pennsylvania.

Adelene Perkins serves as Infinity’s chief executive officer and Infinity’s chair, a position she has held since 2012. She was named chief executive officer and elected to the Board of Directors in 2009. Before serving as CEO, Ms. Perkins served as Infinity’s President, a position she held since 2008. Ms. Perkins joined Infinity in June 2002 as executive vice president and chief business officer. Ms. Perkins joined Infinity from TransForm Pharmaceuticals where she served as vice president of business and corporate development and an early member of the management team that built the company prior to its acquisition by J&J. Prior to TransForm, from 1992-1999, she was at Genetics Institute, now a unit of Pfizer, where she was vice president of emerging businesses and the co-founder and general manager of the DiscoverEase™ business unit. She also formed and served as chief executive officer of MetaMorphix, a joint venture between Genetics Institute and Johns Hopkins University. She joined Genetics Institute in corporate and business development where she led corporate and product strategy initiatives. From 1985-1992, Ms. Perkins worked at Bain & Company, an international strategy consulting firm, where she provided strategic and operational advice to clients in the healthcare industry. Ms. Perkins received her M.B.A. from Harvard Business School and her B.S. in chemical engineering from Villanova University. In addition to chairing the Infinity (NASDAQ: INFI) Board, she is on the Boards of Bruker Corporation (NASDAQ: BRKR), Massachusetts General Hospital, BIO (Biotechnology Industry Organization), the Massachusetts Biotechnology Council, and is the vice chairman of the Board of Project Hope. She is a past member of the Boards of Padlock Therapeutics, prior to its acquisition by Bristol-Myers Squibb, and the Massachusetts Life Science Center.

Paula Brown Stafford is a biopharmaceutical services executive and leadership consultant with more than 30 years of industry experience. She is currently the President and Chief Operating Officer for Novan, Inc., as well as a Managing Director for Habergeon LLC. Ms. Stafford retired in 2015 from her position as President of Clinical Development at Quintiles (now part of iQvia). Ms. Stafford’s global responsibilities encompassed Phase I-IV clinical research services and she served as a member of Quintiles Executive Committee. She was an Independent Director for BioImaging, later BioClinica (NASDAQ: BIOC), from 2002 to 2008. In addition, Ms. Stafford served as a member of the CDISC (Clinical Data Interchange Standards Consortium) Board of Directors for 9 years, serving as Chair for 2 years and as a member of the Executive Committee for 6 years. Ms. Stafford is an Adjunct Professor in Public Health Leadership for the UNC-CH Gillings School of Global Public Health and emeritus member of the UNC-CH Public Health Foundation Board. In 2011, Ms. Stafford received the Triangle Business Journal’s Women in Business Award. FierceBiotech named Ms. Stafford one of the 10 top women in biotech in 2012. Ms. Stafford holds a Bachelor of Science and a Master of Public Health in Biostatistics from the University of North Carolina at Chapel Hill. In 2016, the university honored Ms. Stafford with its Distinguished Alumna Award.

As President and Chief Executive Officer of Seres Therapeutics, I’m focused on leading Seres with the belief that microbiome therapies can transform how disease is treated for individuals managing and living with serious disease. Through the combination of proprietary science, innovative technology and rigorous analysis, we’re striving to create a future that includes a revolutionary way of providing new treatment options to healthcare providers so patients can thrive from the inside out.My more than 20 years of experience working in executive leadership roles in biotechnology finance, corporate development and capital markets, drives me to help ensure Seres’ continued growth within the microbiome industry. Our steadfast commitment-from scientific discovery to fulfilling the promise of recovery-aims to help people live more fulfilling lives.

Shuqi Chen are a Chairman/President/CEO/Founder at IQuum Inc. They have worked as Faculty Member at Harvard University.